- Home
- NI vs GMAB Comparison
NI vs GMAB Comparison
Compare NI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NI | GMAB |
|---|---|---|
| Founded | 1912 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 20.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NI | GMAB |
|---|---|---|
| Price | $41.45 | $33.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $47.00 | $40.40 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | 15.58 | ★ 132.41 |
| EPS | 1.90 | ★ 25.10 |
| Revenue | ★ $6,327,100,000.00 | $3,845,670,022.00 |
| Revenue This Year | $17.34 | $24.85 |
| Revenue Next Year | $3.53 | $16.51 |
| P/E Ratio | $21.90 | ★ $1.35 |
| Revenue Growth | 19.62 | ★ 29.57 |
| 52 Week Low | $35.59 | $17.24 |
| 52 Week High | $44.88 | $33.99 |
Technical Indicators
Market Signals| Indicator | NI | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 62.14 |
| Support Level | $40.83 | $30.35 |
| Resistance Level | $42.36 | $33.96 |
| Average True Range (ATR) | 0.59 | 0.67 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 43.48 | 96.97 |
Price Performance
Historical ComparisonAbout NI NiSource Inc
NiSource is one of the nation's largest natural gas distribution companies with 3.2 million customers in Indiana, Kentucky, Maryland, Ohio, Pennsylvania, and Virginia. NiSource's electric utility transmits and distributes electricity in northern Indiana to about 500,000 customers. The regulated electric utility also owns more than 3,000 megawatts of generation capacity, including coal, natural gas, and renewable energy.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.